Neuroscientific Biopharmaceuticals Secures US FDA Guidance for Glaucoma Medication

Neuroscientific Biopharmaceuticals (ASX:NSB) secured guidance from the US Food and Drug Administration following a pre-investigational new drug meeting for advanced glaucoma medication EmtinB, accordi

MT NewswiresJun 10 23:12 ET

NeuroScientific Biopharmaceuticals Secures AU$2 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 6%

Neuroscientific Biopharmaceuticals (ASX:NSB) secured a AU$2.2 million rebate from the Australian government research and development tax incentive scheme for the fiscal year ended June 30, 2023, accor

MT NewswiresMar 19 20:07 ET

NeuroScientific Biopharmaceuticals Limited's (ASX:NSB) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Yahoo FinanceFeb 28 19:17 ET

NeuroScientific Biopharmaceuticals (ASX:NSB) Secures $3.7m Tax Incentive Refund

The Market HeraldFeb 1, 2023 23:36 ET